NZ543636A - Use of fused heterocyclic compounds as SCCE inhibitors for the treatment of skin conditions or cancer - Google Patents

Use of fused heterocyclic compounds as SCCE inhibitors for the treatment of skin conditions or cancer

Info

Publication number
NZ543636A
NZ543636A NZ543636A NZ54363604A NZ543636A NZ 543636 A NZ543636 A NZ 543636A NZ 543636 A NZ543636 A NZ 543636A NZ 54363604 A NZ54363604 A NZ 54363604A NZ 543636 A NZ543636 A NZ 543636A
Authority
NZ
New Zealand
Prior art keywords
phenyl
oxazin
aza
benzo
oxa
Prior art date
Application number
NZ543636A
Other languages
English (en)
Inventor
Marcel Linschoten
Original Assignee
Arexis Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arexis Ab filed Critical Arexis Ab
Publication of NZ543636A publication Critical patent/NZ543636A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
NZ543636A 2003-06-06 2004-06-07 Use of fused heterocyclic compounds as SCCE inhibitors for the treatment of skin conditions or cancer NZ543636A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200300844 2003-06-06
DKPA200300843 2003-06-06
DKPA200300842 2003-06-06
DKPA200300840 2003-06-06
PCT/DK2004/000388 WO2004108139A2 (en) 2003-06-06 2004-06-07 Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer

Publications (1)

Publication Number Publication Date
NZ543636A true NZ543636A (en) 2009-07-31

Family

ID=33514772

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ543636A NZ543636A (en) 2003-06-06 2004-06-07 Use of fused heterocyclic compounds as SCCE inhibitors for the treatment of skin conditions or cancer

Country Status (17)

Country Link
US (1) US7872052B2 (enExample)
EP (1) EP1631295B1 (enExample)
JP (1) JP5044214B2 (enExample)
KR (2) KR101099409B1 (enExample)
CN (1) CN101152185B (enExample)
AT (1) ATE459359T1 (enExample)
CA (1) CA2525383C (enExample)
CY (1) CY1110084T1 (enExample)
DE (1) DE602004025803D1 (enExample)
DK (1) DK1631295T3 (enExample)
ES (1) ES2341545T3 (enExample)
NO (1) NO20060091L (enExample)
NZ (1) NZ543636A (enExample)
PL (1) PL1631295T3 (enExample)
PT (1) PT1631295E (enExample)
SI (1) SI1631295T1 (enExample)
WO (1) WO2004108139A2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE102004001873A1 (de) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
EP1909788A2 (en) * 2005-07-29 2008-04-16 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2008036379A2 (en) 2006-09-21 2008-03-27 Activx Biosciences, Inc. Serine hydrolase inhibitors
MX2009003673A (es) 2006-10-04 2009-04-22 Pfizer Prod Inc Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio.
SI2118074T1 (sl) 2007-02-01 2014-05-30 Resverlogix Corp. Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
US8415305B2 (en) 2007-08-17 2013-04-09 Novartis Ag Use of cyclic depsipeptides to inhibit kallikrein 7
CN103298827B (zh) 2007-08-17 2017-05-31 诺华股份有限公司 环状酯肽
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010026214A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
NZ594332A (en) 2009-01-08 2013-09-27 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular disease
EP2403857B1 (en) * 2009-03-05 2013-12-04 Takeda Pharmaceutical Company Limited Thienopyrimidine as cdc7 kinase inhibitors
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
DK2414363T3 (da) 2009-03-31 2014-01-27 Boehringer Ingelheim Int 1-heterocyklyl-1,5-dihydro-pyrazol[3,4-d]pyrimidin-4-on-derivater og anvendelse af disse som PDE9A-modulatorer.
BRPI1014956B8 (pt) 2009-04-22 2021-05-25 Resverlogix Corp agentes anti-inflamatórios
TWI419884B (zh) * 2010-06-24 2013-12-21 Univ Chang Gung 苯并雜氧嗪酮衍生物，其製備方法以及包含有此等衍生物的藥學組成物
WO2012020022A1 (en) 2010-08-12 2012-02-16 Boehringer Ingelheim International Gmbh 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
US8614289B2 (en) 2011-04-20 2013-12-24 Novartis Ag Processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
AU2012330885B2 (en) 2011-11-01 2016-10-06 Resverlogix Corp. Oral immediate release formulations for substituted quinazolinones
MX2014011115A (es) 2012-03-16 2015-03-13 Axikin Pharmaceuticals Inc Inhibidores de 3,5-diaminopirazol cinasa.
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
AU2015209761B2 (en) * 2014-01-23 2018-11-29 Sixera Pharma Ab Benzoxazinone derivatives for treatment of skin diseases
US9744148B2 (en) * 2014-01-23 2017-08-29 Sixera Pharma Ab Kallikrein 7 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
US10807994B2 (en) 2017-10-09 2020-10-20 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CN108421034A (zh) * 2018-04-24 2018-08-21 济南磐升生物技术有限公司 激肽释放酶7在皮肤创伤愈合中的应用
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
TWI803696B (zh) 2018-09-14 2023-06-01 日商橘生藥品工業股份有限公司 次黃嘌呤化合物
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
KR20210150476A (ko) 2019-04-09 2021-12-10 누베이션 바이오 인크. 헤테로시클릭 화합물 및 그의 용도
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3151626A1 (en) 2019-10-01 2021-04-08 Molecular Skin Therapeutics, Inc. Benzoxazinone compounds as klk5/7 dual inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP7502945B2 (ja) * 2020-09-08 2024-06-19 花王株式会社 デリケートエリアのかぶれの検査方法
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
EP4346761A1 (en) 2021-06-01 2024-04-10 Sixera Pharma AB Oil-in-water emulsion of 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,l-benzoxazin-4-one
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
AU2023289368A1 (en) * 2022-06-21 2025-01-16 Dana-Farber Cancer Institute, Inc. Fused bicyclic egfr inhibitors and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153994A (en) * 1965-07-21 1969-06-04 Aspro Nicholas Ltd Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them
FR2121341A1 (en) * 1971-01-04 1972-08-25 Ferlux 2-substd-3,1-benzoxazin-4-ones - antiinflammatories, analgesics sedatives and diuretics
IT1050750B (it) * 1975-12-05 1981-03-20 Erba Carlo Spa Derivati della 3.4 di idro chinazolina
JPS5576868A (en) 1978-12-01 1980-06-10 Hisamitsu Pharmaceut Co Inc Novel 3,1-bezoxazine derivative
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
FI912995A0 (fi) 1988-12-21 1991-06-19 Upjohn Co Atiaterosklerotiska och antirombotiska 1-benzopyran-4-oner och 2-amino-1,3-benzoxazin-4-oner.
JPH07316056A (ja) * 1990-02-15 1995-12-05 Teijin Ltd エラスターゼ阻害用医薬組成物
EP0466944A4 (en) * 1990-02-15 1992-07-08 Teijin Limited 4h-3,1-benzoxazin-4-one compound and elastase inhibitor composition containing the same
ATE158288T1 (de) * 1990-06-20 1997-10-15 Upjohn Co Antiatherosklerotische und antithrombotische 1- benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on- derivate
ES2108120T3 (es) * 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5346886A (en) * 1993-11-15 1994-09-13 John Lezdey Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin
WO2000030646A1 (en) * 1998-11-26 2000-06-02 Novo Nordisk A/S Heterocyclic compounds regulating clotting
US6541629B1 (en) * 1999-09-10 2003-04-01 The Procter & Gamble Company Enzyme inhibitors
DK1367886T3 (da) 2001-02-09 2011-10-24 Torbjoern Egelrud SCCE-transgene mus og deres anvendelse som modeller for humane sygdomme
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2004031180A1 (ja) * 2002-10-03 2004-04-15 Institute Of Medicinal Molecular Design. Inc. キナゾリン−４−オン誘導体
CA2502302A1 (en) * 2002-11-04 2004-05-21 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS

Also Published As

Publication number Publication date
NO20060091L (no) 2006-03-06
ATE459359T1 (de) 2010-03-15
HK1091731A1 (zh) 2007-01-26
DE602004025803D1 (de) 2010-04-15
WO2004108139A3 (en) 2005-03-10
AU2004244704A1 (en) 2004-12-16
KR101205257B1 (ko) 2012-11-27
ES2341545T3 (es) 2010-06-22
KR101099409B1 (ko) 2011-12-27
US7872052B2 (en) 2011-01-18
CA2525383A1 (en) 2004-12-16
JP5044214B2 (ja) 2012-10-10
EP1631295A2 (en) 2006-03-08
US20060258651A1 (en) 2006-11-16
CY1110084T1 (el) 2015-01-14
SI1631295T1 (sl) 2010-06-30
CA2525383C (en) 2012-03-06
CN101152185A (zh) 2008-04-02
KR20110120960A (ko) 2011-11-04
DK1631295T3 (da) 2010-06-21
WO2004108139A2 (en) 2004-12-16
KR20060008331A (ko) 2006-01-26
PL1631295T3 (pl) 2010-09-30
HK1120209A1 (en) 2009-03-27
PT1631295E (pt) 2010-05-24
JP2006526581A (ja) 2006-11-24
EP1631295B1 (en) 2010-03-03
CN101152185B (zh) 2010-12-08
WO2004108139A8 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
CA2525383C (en) Use of heterocyclic compounds as scce inhibitors
EP2276767B1 (en) Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
KR20230170039A (ko) Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
JP2011504505A (ja) 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
EA021671B1 (ru) ПЕПТИДОМИМЕТИК Smac, ПРИМЕНИМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА IAP (ИНГИБИТОР БЕЛКОВ АПОПТОЗА)
JP2003526594A (ja) カッパ・アゴニスト抗掻痒薬学的製剤およびそれにより掻痒を治療する方法
JP4588973B2 (ja) 経口投与用製剤
WO2004054582A1 (en) Combination therapy for the treatment of pain
EP2225216A1 (en) Substituted benzoazole pde4 inhibitors for treating pulmonary and cardiovascular disorders
US6180625B1 (en) Heterocyclic compounds regulating clotting
CN100518740C (zh) 杂环化合物作为scce抑制剂的制药用途
WO1999048878A1 (en) Heterocyclic compounds regulating clotting
AU2004244704B2 (en) Use of fused heterocyclic compounds as SCCE inhibitors for the treatment of skin conditions or cancer
HK1091731B (en) Pharmaceutical use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
HK1120209B (en) Use of fused heterocyclic compounds as scce inhibitors
JP2003502362A (ja) 化学療法および／または放射線療法の副作用の苛酷さを防止／軽減するための組成物および方法
KR20140107667A (ko) 이미다조피리딘 유도체의 치료적 용도
WO2000030646A1 (en) Heterocyclic compounds regulating clotting
PL185960B1 (pl) Pochodne 4a, 5a, 8a, 8b-tetrahydro-6H-pirolo[3',4': 4,5]furo[3,2-b]pirydyno-6,8(7H)-dionu, sposób ich wytwarzania i ich zastosowanie oraz kompozycja do zwalczania pasożytów wewnętrznych
ES2349142T3 (es) Derivados de ditiolopirrolona útiles en el tratamiento de enfermedades proliferativas.
HK1147741B (en) Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 JUN 2017 BY LEA SKYLLERSTEDT

Effective date: 20140520

LAPS Patent lapsed